Table of Contents
Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis
Related Topics
Chronic Kidney Disease (CKD) Nutritional Supplements Market Size Cardiovascular Diagnostic and Monitoring Market Size Heat Recovery Ventilator Market Size Airflow and Zone Controls Equipment Market SizeGlobal Chronic Kidney Disease (CKD) Drug Market Size to Exceed USD 20.80 Billion by 2033
According to a research report published by Spherical Insights & Consulting, The Global Chronic Kidney Disease (CKD) Drug Market Size is Expected to Grow from USD 14.2 Billion in 2023 to USD 20.80 Billion by 2033, at a CAGR of 3.89% during the forecast period 2023-2033.
Browse 210 market data Tables and 45 Figures spread through 190 Pages and in-depth TOC on the Global Chronic Kidney Disease (CKD) Drug Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis-stimulating Agents (ESAs), Diuretics, and Others), By End-User (Hospitals and Specialty Clinics), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.
The chronic kidney disease (CKD) drug market is the international industry dedicated to the development, manufacturing, and distribution of prescription drugs for treating and controlling chronic kidney disease (CKD). The market comprises drugs that help slow the progress of the disease, control its complications, and enhance the well-being of patients with CKD. Furthermore, the global chronic kidney disease (CKD) drug market is being pushed by growing cases of CKD, the aging population, and mounting awareness about treating and diagnosing CKD earlier. Developing treatments, expanding health infrastructure, beneficial government policies, and higher demand for individualized medicine add momentum to the growth of the market. Enhanced reimbursement policies and rising healthcare expenditures further fuel market growth. However, the high treatment costs, stringent regulatory approvals, limited patient awareness, reimbursement challenges, side effects of CKD drugs, and restricted access in low-income regions are key restraints for the growth of the market.
The ACE inhibitors segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.
On the basis of the drug class, the global chronic kidney disease (CKD) drug market is divided into ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents (ESAs), diuretics, and others. Among these, the ACE inhibitors segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segmental growth is attributed to their proven effectiveness in slowing CKD progression, reducing blood pressure, and protecting kidney function. Increasing CKD prevalence, widespread physician preference, and rising awareness about early disease management further drive the segment’s significant CAGR during the forecast period.
The hospitals segment accounted for the largest share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.
On the basis of the end-user, the global chronic kidney disease (CKD) drug market is divided into hospitals and specialty clinics. Among these, the hospitals segment accounted for the largest share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period. The segmental growth is attributed to the high number of CKD patient admissions, the availability of advanced treatment options, and the presence of skilled healthcare professionals. Increasing government healthcare investments, improved diagnostic capabilities and the rising adoption of specialized CKD drugs further drive the segment’s remarkable CAGR during the forecast period.
North America is projected to hold the largest share of the global chronic kidney disease (CKD) drug market over the forecast period.
North America is projected to hold the largest share of the global chronic kidney disease (CKD) drug market over the forecast period. The regional growth is expanded to the high prevalence of CKD, advanced healthcare infrastructure, and the strong presence of key pharmaceutical companies. Favorable reimbursement policies, increasing healthcare expenditure, rising awareness about early disease management, and continuous advancements in drug development further drive the region’s significant market share during the forecast period.
Asia Pacific is expected to grow at the fastest CAGR growth of the global chronic kidney disease (CKD) drug market during the forecast period. The regional growth is attributed to the rising prevalence of CKD, increasing healthcare investments, and expanding access to advanced treatments. Growing awareness, a large aging population, government initiatives, and the presence of emerging pharmaceutical markets further drive the region’s rapid expansion in the CKD drug market during the forecast period.
Company Profiling
Major vendors in the global chronic kidney disease (CKD) drug market are F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi, GSK plc, Kissei Pharmaceutical Co., Ltd., AbbVie Inc., Akebia Therapeutics, Inc., AstraZeneca, Amgen Inc., Teva Pharmaceutical Industries Ltd., and others.
Key Target Audience
Recent Development
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global chronic kidney disease (CKD) drug market based on the below-mentioned segments:
Global Chronic Kidney Disease (CKD) Drug Market, By Drug Class
Global Chronic Kidney Disease (CKD) Drug Market, By End-User
Global Chronic Kidney Disease (CKD) Drug Market, By Regional
May 2025 - The Global Chronic Kidney Disease Treatment Market Size is Expected to Grow from USD 33.20 Billion in 2023 to USD 47.99 Billion by 2033, at a CAGR of 3.75% during the forecast period 2023-2033
May 2025 - The Global Chronic Kidney Disease Market Size is Expected to Grow from USD 38.30 Billion in 2023 to USD 66.65 Billion by 2033, at a CAGR of 5.70% during the forecast period 2023-2033
May 2025 - The Global Chronic Kidney Disease (CKD) Nutritional Supplements Market Size is Expected to Grow from USD 3.56 Billion in 2023 to USD 5.20 Billion by 2033, at a CAGR of 3.86% during the forecast period 2023-2033
We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.
